Trials / Conditions / Substance Withdrawal Syndrome

Substance Withdrawal Syndrome

25 registered clinical trials studyying Substance Withdrawal Syndrome.

Status	Trial	Sponsor	Phase
Unknown	EA for PAAS: A pRCT NCT04917185	Chengdu University of Traditional Chinese Medicine	N/A
Completed	Signs and Symptoms of Opioid-associated Iatrogenic Withdrawal in Critically Ill Adults NCT03435614	Marc M. Perreault	—
Completed	Opioid Withdrawal Symptoms in Critically Ill Patients NCT03374722	Mahidol University	—
Completed	Does Abstinence From E-cigarettes Produce Withdrawal Symptoms? NCT02825459	University of Vermont	N/A
Completed	Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose NCT02801357	USWM, LLC (dba US WorldMeds)	Phase 1
Unknown	Abuse and Addiction in ICU NCT02951793	Seoul National University Hospital	—
Completed	Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED NCT02643355	Hennepin Healthcare Research Institute	N/A
Completed	The Effect of Melatonin Upon Post-Acute Withdrawal Among Males in a Residential Treatment Program NCT02431728	Duquesne University	Phase 1 / Phase 2
Completed	Opioids Withdrawal Syndrome in Critically Ill Patients: a Multicenter Prospective Cohort Study NCT02318290	Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal	—
Completed	Process Evaluation Standardised Nurse-led Approach for Risk Screening and Decrease of Alcohol Withdrawal in EN NCT02782156	University Hospital, Basel, Switzerland	—
Completed	Electronic Cigarettes in Daily Dependent Smokers NCT02108626	Centre for Addiction and Mental Health	Phase 4
Completed	Nicotine Replacement Therapy in the Intensive Care Unit NCT01362959	Gelderse Vallei Hospital	Phase 4
Completed	Stopping Benzodiazepines and Related Molecules Among Elderly Living in Residential Institutions NCT02715440	Assistance Publique - Hôpitaux de Paris	N/A
Withdrawn	Validation of a Pediatric-Specific Abstinence Syndrome Assessment Tool NCT00792415	Banner Health	—
Completed	Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal NCT00980044	Michelle Lofwall	Phase 2 / Phase 3
Completed	The Effects of One-Time Pregnenolone, Dehydroepiandrosterone (DHEA), or Placebo Administration On Withdrawal S NCT00900900	Jed E. Rose	Phase 2
Completed	Therapeutic Massage to Manage Withdrawal Related Anxiety NCT00992979	Dalhousie University	Phase 2
Completed	Effect of Ondansetron for Withdrawal Symptoms NCT00695864	Stanford University	N/A
Completed	Lithium Cannabis Withdrawal Study NCT00114439	Sydney South West Area Health Service	Phase 2
Completed	The Effect of Valproate on Benzodiazepine Withdrawal Severity NCT00570219	University of Helsinki	N/A
Completed	Treatment of Polydrug-Using Opiate Dependents During Withdrawal NCT00367874	Sorlandet Hospital HF	Phase 4
Completed	Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1 NCT00032955	University of California, Los Angeles	Phase 3
Completed	Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1 NCT00032968	University of California, Los Angeles	Phase 3
Completed	Acute Withdrawal From Smoked Cocaine - 9 NCT00000292	National Institute on Drug Abuse (NIDA)	Phase 1
Completed	Effects of Dynorphin 1-13 on Heroin Addiction - 1 NCT00000244	University of Minnesota	Phase 2